Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review

Otto, Suzie J.; Fracheboud, Jacques; Looman, Caspar W. N.; Broeders, Mireille J. M.; Boer, R. de; Hendriks, Jan H. C. L.; Verbeek, A.L.M.; Koning, Harry J. de

doi:10.1016/s0140-6736(03)13132-7

Cited by 296 publications

(210 citation statements)

References 21 publications

Supporting

Mentioning

191

Contrasting

Unclassified

Order By: Relevance

“…In fact, the breast cancer mortality in Dutch women aged 55 -74 started to decline significantly from 1997 onwards (Otto et al, 2003). After recalculation of the incidence rates for the same age band, we found a significant reduction of advanced diseases already in 1995, preceding the breast cancer mortality reduction of a similar extent by 2 years (Table 3).…”

Section: %mentioning

confidence: 64%

“…In the 'old' regions, the decline in this age category was larger, with an EAPC of À5.5 (95% CI À8.52, À2.37; data not shown). Table 3 compares the incidence rates of advanced breast cancers with the breast cancer mortality in The Netherlands (all nine (Otto et al, 2003). This reduction of advanced diseases precedes the observed significant breast cancer mortality reduction of a comparable extent by approximately 2 years.…”

Section: Resultsmentioning

confidence: 93%

“…The significance level of differences in advanced cancer incidence rates was estimated by means of the expected standard deviation of the difference in incidence rate of a certain year and age group compared with 1989, according to the method that we used for assessing changes in breast cancer mortality (van den Akker-van Marle et al, 1999;Otto et al, 2003). Table 1 gives the age-adjusted combined invasive and in situ breast cancer incidence rates in 1989 -1997 and the percent change compared with 1989 by different age categories.…”

Section: Methodsmentioning

confidence: 99%

“…As we observed a significant decrease in breast cancer mortality within the population targeted for screening as of 1997 (Otto et al, 2003), we assumed a decline in advanced disease stages as well. For this reason, we focused our analyses on trends in advanced tumour stages in the seven regions that started screening activities after 1990 ('new' regions).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Decreased rates of advanced breast cancer due to mammography screening in The Netherlands

et al. 2004

View full text Add to dashboard Cite

The effect of the implementation of the Dutch breast cancer screening programme during 1990 -1997 on the incidence rates of breast cancer, particularly advanced breast cancer, was analysed according to stage at diagnosis in seven regions, where no screening took place before 1990. The Netherlands Cancer Registry provided detailed data on breast cancer incidence in 1989 -1997 by tumour stage, age and region. Annual age-adjusted incidence rates of all breast cancers and advanced cancers, defined as large tumours T2 þ with lymph node and/or distant metastases, were compared with rates in 1989. In general, breast cancer incidence rose strongly in the early 1990s, especially in the age category 50 -69 years (estimated annual percentage change (EAPC) 4.25; 95% CI 1.70, 6.86). The increase was mainly due to the increase in small T1 cancers and ductal carcinoma in situ. However, in women aged 50 -69, advanced cancer incidence rates showed a significant decline by 12.1% in 1997 compared with 1989 (EAPC -2.14, 95% CI À3.47, À0.80), followed by a breast cancer mortality reduction of similar size after approximately 2 years. We confirm that breast cancer screening initially leads to a temporary strong increase in the breast cancer incidence, which is followed by a significant decrease in advanced diseases in the women invited for screening. It is evident that breast cancer screening contributes to a reduction in advanced breast cancers and breast cancer mortality.

show abstract

Section: %mentioning

confidence: 64%

Section: Resultsmentioning

confidence: 93%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Decreased rates of advanced breast cancer due to mammography screening in The Netherlands

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Mammographic screening has been shown to reduce breast cancer mortality rates (Vainio and Bianchini, 2002). Several studies in northern European countries (Hermon and Beral, 1996;Hakama et al, 1997; Van den Akker-van Marle et al, 1999;Blanks et al, 2000;Jonsson et al, 2001;Botha et al, 2003;Otto et al, 2003;Tabar et al, 2003) have reported a decrease in breast cancer mortality where nationwide screening programmes have been implemented. There has, however, been considerable debate concerning the relative contributions of screening and of improved therapy to the observed trends (Carnon et al, 1996;Blanks et al, 2000;Peto et al, 2000).…”

mentioning

confidence: 99%

Breast cancer mortality trends in two areas of the province of Florence, Italy, where screening programmes started in the 1970s and 1990s

et al. 2004

View full text Add to dashboard Cite

We compared breast cancer mortality rates in the period 1985 -2000 in two areas of the province of Florence, Italy, where breast cancer screening programmes started in the 1970s (early screening (ES) area) and in 1990s (late screening (LS) area). The overall age-standardised mortality decreased in the whole period by 40.9% in the ES area (Po0.001), and by 11.3% in the LS area (P ¼ 0.030). Significant decreases in the ES area were detected in groups aged 45 -54 years (61.1%; P ¼ 0.018) and 65 -74 years (44.7%; P ¼ 0.049), whereas in the LS area no significant decrease was detected in any age group. The relatively low compliance in the first years of the programme in both areas, and the long enrolment period in the LS area could have reduced the effect on mortality. Our findings suggest that the drop in mortality in the ES area (41%) could be explained by both service screening and better care. The slight decrease in mortality in the LS area (11%) could be mainly due to better care. A reduction of about 30% is attributable to screening in the ES area over the period 1985 -2000. Mammographic screening has been shown to reduce breast cancer mortality rates (Vainio and Bianchini, 2002). Several studies in northern European countries (Hermon and Beral, 1996;Hakama et al, 1997; Van den Akker-van Marle et al, 1999;Blanks et al, 2000;Jonsson et al, 2001;Botha et al, 2003;Otto et al, 2003;Tabar et al, 2003) have reported a decrease in breast cancer mortality where nationwide screening programmes have been implemented. There has, however, been considerable debate concerning the relative contributions of screening and of improved therapy to the observed trends (Carnon et al, 1996;Blanks et al, 2000;Peto et al, 2000).At the beginning of the 1970s in 23 rural municipalities of the province of Florence, Italy (early screening area (ES area) among about 70 000 resident women aged 25 or over, 18% of women of the province, based on 1991 Census), a mammographic screening programme was started; until 1989, women in the 40 -69 year age group were invited, whereas from that year onwards the target population was restricted to age group 50 -69 years. The number of mammograms performed in the ES area was 8000 -9000 per year. The efficacy of the programme on breast cancer mortality in the ES area has been evaluated for the period 1977 -1984 by means of case -control studies (Palli et al, 1986(Palli et al, , 1989, and by using early indicators of efficacy (Paci et al, 1990). After 1990, when the screening for women aged 50 -69 years started in the rest of the province, including the city of Florence (late screening area: LS area), the number of mammograms in the whole province increased to 28 000 -29 000 per year (Barchielli et al, 1999).In this study, we have compared breast cancer mortality rates in the period 1985 -2000 in the ES and LS areas. MATERIALS AND METHODS Sources of data Statistical analysisAdjusted mortality and incidence rates using direct standardisation to the European Standard Population, and age-specific (35 -44, 45 -...

show abstract

Breast Cancer Screening for Women at Average Risk

Oeffinger

Fontham

Etzioni

et al. 2015

JAMA

1,439

906

View full text Add to dashboard Cite

Importance Breast cancer is a leading cause of premature mortality among U.S. women. Early detection has been shown to be associated with reduced breast cancer morbidity and mortality. This report updates the American Cancer Society (ACS) 2003 breast cancer screening guideline for women at average risk for breast cancer. Process The ACS commissioned a systematic evidence review of the breast cancer screening literature to inform the update, and a supplemental analysis of mammography registry data to address questions related to the screening interval. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms. Evidence Synthesis Mammography screening in women aged 40–69 years is associated with a reduction in breast cancer deaths across a range of study designs, and inferential evidence supports breast cancer screening in women who are age 70 years and older and are in good health. Estimates of the cumulative lifetime risk of false positive exams are greater if screening begins at younger ages due to the greater number of mammograms, as well as the higher recall rate in younger women. The quality of the evidence for overdiagnosis is not sufficient to estimate a lifetime risk with confidence. Analysis examining the screening interval demonstrates more favorable tumor characteristics when premenopausal women are screened annually vs. biennially. Evidence does not support routine clinical breast examination as a screening method for average risk women. Recommendations The ACS recommends that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years (strong recommendation). Women who are ages 45 to 54 years should be screened annually (qualified recommendation). Women who are age 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation). Women should have the opportunity to begin annual screening between the ages of 40 and 44 years (qualified recommendation). Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or more (qualified recommendation). The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age (qualified recommendation).

show abstract

Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review

Cited by 296 publications

References 21 publications

Decreased rates of advanced breast cancer due to mammography screening in The Netherlands

Decreased rates of advanced breast cancer due to mammography screening in The Netherlands

Breast cancer mortality trends in two areas of the province of Florence, Italy, where screening programmes started in the 1970s and 1990s

Breast Cancer Screening for Women at Average Risk

Contact Info

Product

Resources

About